|
(Health-NewsWire.Net, October 14, 2020 ) The objectives of this study are as follows:
# To define, describe, and forecast the global Creatinine Assay Tests Market on the basis of type, type of sample, and region.
# To estimate the total number of Creatinine Measurement tests conducted by type and region.
# To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges).
# To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market.
# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for the market leaders.
# To forecast the size of the market with respect to five regions: North America, Europe, Asia, and the Rest of the World (RoW).
# To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
# To track and analyze competitive developments in the creatinine assay kits industry, such as acquisitions, agreements, product launches & upgrades, expansions, and R&D activities.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=73499229
The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. Increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders are the key drivers of the global creatinine assay kits market.
Market Segmentation:
Based on type of sample, the blood/serum segment is expected to register the highest CAGR during the forecast period
Based on type of sample, the creatinine assay tests market is segmented into blood/serum, urine, and other samples. Other samples mainly include saliva, cerebrospinal fluid, tissue homogenate, and sweat. The blood/serum segment is expected to witness the highest CAGR over the forecast period. Most newly developed creatinine measurement kits are based on the analysis of creatinine in blood samples owing to its accuracy in inferring creatinine concentration. These are the major factors responsible for the increasing adoption of this sample type.
The Jaffe’s kinetic test kits segment dominated the market in 2017
The creatinine assay kits market, by type, is segmented into Jaffe’s kinetic test kits, creatinine-PAP test kits, and ELISA test kits. In 2017, Jaffe’s kinetic test kits accounted for the largest share of the market. Jaffe’s kinetic test is the oldest and most conventional method for creatinine measurement. Additionally, the wide product availability, as well as the cost-effectiveness of these kits, are some of the major factors responsible for the large share of this segment.
Geographical Growth:
In 2017, North America dominated the creatinine assay tests market
In 2017, North America dominated the market followed by Europe. The large share of North America is attributed to factors such as increasing incidence of renal disorders, rising prevalence of other chronic disorders like hypertension and diabetes (which can lead to renal dysfunction), and the implementation of favorable government initiatives to increase awareness of and encourage research pertaining to kidney diseases.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=73499229
Key Players:
The creatinine assay kits market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Crystal Chem (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
